Objective: Renal dysfunction following cardiac surgery is more apparent in high-risk patients with pre-existing renal dysfunction, diabetes and impaired left-ventricular function, and following complicated procedures involving prolonged cardiopulmonary bypass (CPB). The aim of this prospectively randomised double-blinded placebo-controlled study was to evaluate reno-protective effect of low-dose furosemide infusion in this high-risk group. Methods: Patients with preoperative serum creatinine >130 mmol/l (1.4 mg/dl), left-ventricular ejection fraction <50%, congestive heart failure, diabetes, or procedures involving prolonged CPB were randomised to receive either saline at 2 ml/h (n = 21), or furosemide at 4 mg/h (n = 21). Infusion was commenced after induction of anaesthesia and continued for 12 h postoperatively. Renal dysfunction was defined as >50% increase in serum creatinine postoperatively, or >130 mmol/l (1.4 mg/dl), or requirement for haemodialysis, or all of these. In patients with preoperative serum creatinine >130 mmol/l, >50% increase over preoperative levels was used to define postoperative renal dysfunction. Results: Following cardiac surgery, patients receiving furosemide had a higher urine output (3.4 AE 1.2 ml/kg/h in furosemide group and 1.2 AE 0.5 ml/kg/h in placebo group; p < 0.001), higher postoperative fluid requirement (4631 AE 1359 ml in furosemide group and 3714 AE 807 ml in placebo group, p = 0.011), and lower urinary-creatinine (2 AE 1.3 mmol/l in furosemide group and 5.9 AE 2.5 mmol/l in placebo group p < 0.001). Both groups had significant increase in retinol binding protein/creatinine ratio (7.2 AE 6 to 3152 AE 1411 in furosemide group; 4.9 AE 2.1 to 2809 AE 1125 in placebo group; p < 0.001) and peak serum creatinine (98 AE 33 to 177 AE 123 mmol/l in furosemide group; 96 AE 20 to 143 AE 87 mmol/l in placebo group; p < 0.001), and a significant decrease in peak creatinine-clearance (64.3 AE 29.4 to 39.1 AE 16.6 ml/min in furosemide group; 65.5 AE 38.6 to 41.8 AE 17.8 ml/min in placebo group; p < 0.001) following cardiac surgery, implying significant renal injury following cardiac surgery. Peak creatinine levels (177 AE 123 mmol/l in furosemide group and 143 AE 87 mmol/l in placebo group; p = 0.35) and peak creatinine-clearance (39.1 AE 16.6 ml/min in furosemide group and 41.8 AE 17.8 ml/min in placebo group; p = 0.61) were similar in the two groups. Importantly, there was no difference in incidence of renal dysfunction between the furosemide group (9/21) and the control group (8/21) (relative risk 1.1, 95% confidence interval 0.6-2.2; p = 0.99). Conclusions: Our randomised trial did not demonstrate any benefit of furosemideinfusion postoperatively in high-risk cardiac surgical patients. Although urinary output increased with furosemide, there was no decrease in renal injury, and no decrease in incidence of renal dysfunction. #
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.